Foghorn Therapeutics logo

Foghorn Therapeutics Share Price (NASDAQ: FHTX)

$5.09

0.08

(1.6%)

Last updated on

Check the interactive Foghorn Therapeutics Stock chart to analyse performance

Foghorn Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

  • Today's Low:$4.92
    Today's High:$5.09

    Day's Volatility :3.34%

  • 52 Weeks Low:$2.94
    52 Weeks High:$10.25

    52 Weeks Volatility :71.27%

Foghorn Therapeutics Stock Returns

PeriodFoghorn Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
21.7%
3.6%
0.0%
6 Months
17.48%
-7.7%
0.0%
1 Year
-35.35%
-12.6%
0.0%
3 Years
-49.5%
9.5%
-4.7%

Foghorn Therapeutics Inc Key Stats

Check Foghorn Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$5.01
Open
$4.92
Today's High
$5.09
Today's Low
$4.92
Market Capitalization
$305.8M
Today's Volume
$77.5K
52 Week High
$10.25
52 Week Low
$2.9448
Revenue TTM
$24.2M
EBITDA
$-88.7M
Earnings Per Share (EPS)
$-1.14
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-470.38%

Stock Returns calculator for Foghorn Therapeutics Stock including INR - Dollar returns

The Foghorn Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Foghorn Therapeutics investment value today

Current value as on today

₹66,758

Returns

₹33,242

(-33.24%)

Returns from Foghorn Therapeutics Stock

₹38,527 (-38.53%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Foghorn Therapeutics Stock

60%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Foghorn Therapeutics Stock from India on INDmoney has increased by 60% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Foghorn Therapeutics Inc

  • Name

    Holdings %

  • Flagship Ventures Management, Inc.

    22.42%

  • FMR Inc

    9.89%

  • Bvf Inc

    9.38%

  • Deerfield Management Co

    5.76%

  • BlackRock Inc

    3.53%

  • Vanguard Group Inc

    3.33%

Analyst Recommendation on Foghorn Therapeutics Stock

Rating
Trend

Buy

    81%Buy

    18%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for Foghorn Therapeutics(by analysts ranked 0 to 5 stars)

Foghorn Therapeutics Share Price Target

What analysts predicted

Upside of 129.21%

Target:

$11.67

Current:

$5.09

Foghorn Therapeutics share price target is $11.67, a slight Upside of 129.21% compared to current price of $5.09 as per analysts' prediction.

Foghorn Therapeutics Stock Insights

  • Price Movement

    In the last 7 days, FHTX stock has moved down by -8.7%
  • Increasing Revenue

    Revenue is up for the last 3 quarters, 2.85M → 7.55M (in $), with an average increase of 36.6% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -19.50M → -17.93M (in $), with an average increase of 4.3% per quarter
  • FHTX vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 108.6%
  • FHTX vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 164.9%
  • Price to Sales

    ForFHTX every $1 of sales, investors are willing to pay $13.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Foghorn Therapeutics Technicals Summary

Sell

Neutral

Buy

Foghorn Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Foghorn Therapeutics Inc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Foghorn Therapeutics Inc logo
-3.33%
17.48%
-35.35%
-49.5%
-71.99%
Regeneron Pharmaceuticals, Inc. logo
6.48%
-15.2%
-50.31%
-3.3%
-2.01%
Beone Medicines Ltd logo
1.77%
24.81%
62.78%
79.11%
29.69%
Vertex Pharmaceuticals Incorporated logo
-14.45%
-19.13%
-17.84%
34.68%
41.87%
Alnylam Pharmaceuticals, Inc. logo
13.79%
83.28%
75.87%
111.28%
242.25%

About Foghorn Therapeutics Inc

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Organization
Foghorn Therapeutics
Employees
112
CEO
Ms. Karin Hellsvik
Industry
Health Technology

Key Management of Foghorn Therapeutics Inc

NameTitle
Mr. Adrian H. B. Gottschalk
President, CEO & Director
Mr. Kristian Humer M.B.A.
Chief Financial Officer
Dr. Anna Rivkin Ph.D.
Chief Business Officer
Dr. Gerald R. Crabtree M.d.
Founder & Member of Scientific Advisory Board
Dr. Steven F. Bellon Ph.D.
Chief Scientific Officer
Ms. Karin Hellsvik
Chief of Staff to the CEO, VP of Corporate Affairs & Investor Relations
Mr. Michael J. LaCascia J.D.
Chief Legal Officer
Mr. Saurabh Sewak Ph.D.
Vice President of Corporate Development
Mr. Carlos Costa
Chief People Officer
Dr. Alfonso Quintas Cardama M.D.
Chief Medical Officer

Important FAQs about investing in FHTX Stock from India :

What is Foghorn Therapeutics share price today?

Foghorn Therapeutics share price today is $5.09 as on at the close of the market. Foghorn Therapeutics share today touched a day high of $5.09 and a low of $4.92.

What is the 52 week high and 52 week low for Foghorn Therapeutics share?

Foghorn Therapeutics share touched a 52 week high of $10.25 and a 52 week low of $2.94. Foghorn Therapeutics stock price today i.e. is closed at $5.09, lower by 50.34% versus the 52 week high.

How to invest in Foghorn Therapeutics Stock (FHTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Foghorn Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Foghorn Therapeutics Shares that will get you 0.2947 shares as per Foghorn Therapeutics share price of $5.09 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Foghorn Therapeutics Stock (FHTX) from India?

Indian investors can start investing in Foghorn Therapeutics (FHTX) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Foghorn Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Foghorn Therapeutics share’s latest price of $5.09 as on August 30, 2025 at 1:29 am IST, you will get 1.9646 shares of Foghorn Therapeutics. Learn more about fractional shares .

What are the returns that Foghorn Therapeutics has given to Indian investors in the last 5 years?

Foghorn Therapeutics stock has given -71.99% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?